Cargando…

ANalgesic Efficacy and safety of MOrphiNe versus methoxyflurane in patients with acute myocardial infarction: the rationale and design of the ANEMON-SIRIO 3 study: a multicentre, open-label, phase II, randomised clinical trial

INTRODUCTION: The unfavourable influence of morphine on the pharmacokinetics of ticagrelor resulting in weaker and retarded antiplatelet effect in patients with acute coronary syndrome (ACS) has been previously shown. Replacing morphine with methoxyflurane, a potent, non-opioid analgesic agent, that...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kubica, Aldona, Kosobucka, Agata, Niezgoda, Piotr, Adamski, Piotr, Buszko, Katarzyna, Lesiak, Maciej, Wojakowski, Wojciech, Gasior, Mariusz, Gorący, Jarosław, Kleinrok, Andrzej, Nadolny, Klaudiusz, Navarese, Eliano, Kubica, Jacek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8098993/ https://www.ncbi.nlm.nih.gov/pubmed/33649058 http://dx.doi.org/10.1136/bmjopen-2020-043330

Ejemplares similares

Influence of METHoxyflurane on ANtiplatelet Effect of ticagrelor in patients with unstable angina pectoris: Rationale and a protocol of a randomized clinical METHANE-SIRIO 4 study
por: Niezgoda, Piotr, et al.
Publicado: (2022)

IMPACT of PCSK9 inhibition on clinical outcome in patients during the inflammatory stage of the SARS-COV-2 infection: Rationale and protocol of the IMPACT-SIRIO 5 study
por: Kubica, Jacek, et al.
Publicado: (2022)

Low-dose ticagrelor with or without acetylsalicylic acid in patients with acute coronary syndrome: Rationale and design of the ELECTRA-SIRIO 2 trial
por: Kubica, Jacek, et al.
Publicado: (2022)

Determinants of the Level of Anti-SARS-CoV-2 IgG ANTibodiEs after Vaccination (DANTE-SIRIO 7) Study in a Large Cohort of Healthcare Workers
por: Krintus, Magdalena, et al.
Publicado: (2022)

Effects of Multidisciplinary Rehabilitation Program in Patients with Long COVID-19: Post-COVID-19 Rehabilitation (PCR SIRIO 8) Study
por: Ostrowska, Małgorzata, et al.
Publicado: (2023)

Metabolism of ticagrelor in patients with acute coronary syndromes
por: Adamski, Piotr, et al.
Publicado: (2018)

Determinants of high platelet reactivity in patients with acute coronary syndromes treated with ticagrelor
por: Adamski, Piotr, et al.
Publicado: (2019)

Ion channel inhibition with amiodarone or verapamil in symptomatic hospitalized nonintensive-care COVID-19 patients: The RECOVERY-SIRIO randomized trial
por: Navarese, Eliano P., et al.
Publicado: (2022)

Andexanet alfa — Recommendations for clinical use. Multidisciplinary experts’ standpoint
por: Kubica, Jacek, et al.
Publicado: (2023)

Pre-hospital treatment of patients with acute coronary syndrome: Recommendations for medical emergency teams. Expert position update 2022
por: Kubica, Jacek, et al.
Publicado: (2022)

Impact of COVID‐19 pandemic on acute heart failure admissions and mortality: a multicentre study (COV‐HF‐SIRIO 6 study)
por: Kubica, Jacek, et al.
Publicado: (2021)

Morphy, P.
Publicado: (1923)

Oral NAloxone to overcome the moRphine effect in acute COronary syndrome patients treated with TICagrelor — NARCOTIC trial
por: Niezgoda, Piotr, et al.
Publicado: (2022)

Comparison of reorganized versus unaltered cardiology departments during the COVID-19 era: A subanalysis of the COV-HF-SIRIO 6 study
por: Ostrowska, Małgorzata, et al.
Publicado: (2022)

Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial
por: Kubica, Jacek, et al.
Publicado: (2016)

Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study
por: Adamski, Piotr, et al.
Publicado: (2017)

Mild therapeutic hypothermia or targeted temperature management for cardiac arrest survivors?
por: Kubica, Jacek, et al.
Publicado: (2022)

Therapy Discontinuation after Myocardial Infarction
por: Pietrzykowski, Łukasz, et al.
Publicado: (2020)

Pretreatment with P2Y(12) Receptor Inhibitors in Acute Coronary Syndromes—Is the Current Standpoint of ESC Experts Sufficiently Supported?
por: Niezgoda, Piotr, et al.
Publicado: (2023)

Pharmacokinetic Modeling of Morphine’s Effect on Plasma Concentrations of Ticagrelor and Its Metabolite in Healthy Volunteers
por: Buszko, Katarzyna, et al.
Publicado: (2021)

Genetic determinants of platelet response to clopidogrel
por: Kubica, Aldona, et al.
Publicado: (2011)

PCSK9 Inhibition During the Inflammatory Stage of SARS-CoV-2 Infection
por: Navarese, Eliano P., et al.
Publicado: (2023)

Sirio
por: Stapledon, Olaf
Publicado: (1973)

The impact of readiness to discharge from hospital on adherence to treatment in patients after myocardial infarction
por: Kosobucka, Agata, et al.
Publicado: (2022)

Determinants of Lipid Parameters in Patients without Diagnosed Cardiovascular Disease—Results of the Polish Arm of the EUROASPIRE V Survey
por: Ratajczak, Jakub, et al.
Publicado: (2023)

Usefulness of C-reactive protein as a marker of early post-infarct left ventricular systolic dysfunction
por: Swiatkiewicz, Iwona, et al.
Publicado: (2012)

Adherence to treatment assessed with the Adherence in Chronic Diseases Scale in patients after myocardial infarction
por: Kosobucka, Agata, et al.
Publicado: (2018)

Medication adherence and its determinants in patients after myocardial infarction
por: Pietrzykowski, Łukasz, et al.
Publicado: (2020)

A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, placebo-controlled, investigator-initiated, multicenter clinical study
por: Kubica, Jacek, et al.
Publicado: (2021)

Inhibitors of sodium-glucose transport protein 2: A new multidirectional therapeutic option for heart failure patients
por: Kubica, Jacek, et al.
Publicado: (2023)

Stratified Approaches to Antiplatelet Therapies Based on Platelet Reactivity Testing
por: Ostrowska, Małgorzata, et al.
Publicado: (2019)

Statins and Risk of New-Onset Diabetes Mellitus: is there a Rationale for Individualized Statin Therapy?
por: Navarese, Eliano Pio, et al.
Publicado: (2013)

Long-term outcome of rotational atherectomy according to burr-to-artery ratio and changes in coronary artery blood flow: Observational analysis
por: Nowak, Aleksander, et al.
Publicado: (2022)

Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI and NSTEMI Patients (PINPOINT): protocol for a prospective, observational, single-centre study
por: Adamski, Piotr, et al.
Publicado: (2017)

ACS network-based implementation of therapeutic hypothermia for the treatment of comatose out-of-hospital cardiac arrest survivors improves clinical outcomes: the first European experience
por: Kozinski, Marek, et al.
Publicado: (2013)

Diurnal Variability of Platelet Aggregation in Patients with Myocardial Infarction Treated with Prasugrel and Ticagrelor
por: Adamski, Piotr, et al.
Publicado: (2022)

Methoxyflurane nephropathy.
por: Mazze, R I
Publicado: (1976)

Five-Year Comparative Efficacy of Everolimus-Eluting vs. Resolute Zotarolimus-Eluting Stents in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
por: Koni, Endrin, et al.
Publicado: (2021)

High-risk percutaneous coronary intervention with Impella CP hemodynamic support. A case series and method presentation
por: Sukiennik, Adam, et al.
Publicado: (2017)

Risk of Statin-Induced Hypertransaminasemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Villani, Rosanna, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ufndfcdh8efkcnphqs3ao263la